Sotera Health (SHC) EBITDA (2020 - 2026)

Sotera Health has reported EBITDA for 7 years, with the latest figure at $109.8 million in Q2 2026.

• On a quarterly basis, EBITDA rose 12.36% year-over-year to $109.8 million in Q2 2026; TTM through Jun 2026 was $411.3 million, a 21.79% increase from a year earlier, with the FY2025 full-year figure at $392.8 million, up 31.97% from the prior year.
• EBITDA was $109.8 million for Q2 2026 at Sotera Health, up from $78.9 million in the prior quarter.
• The five-year high for EBITDA was $114.3 million in Q3 2025, with the low at $33.4 million in Q1 2023.
• Average EBITDA over 5 years is $78.0 million, with a median of $76.4 million recorded in 2023.
• The largest YoY upside for EBITDA was 72.89% in 2023 against a maximum downside of 37.62% in 2023.
• Over 5 years, EBITDA stood at $60.2 million in 2022, then surged by 72.89% to $104.0 million in 2023, then decreased by 16.23% to $87.1 million in 2024, then gained by 24.4% to $108.4 million in 2025, then climbed by 1.29% to $109.8 million in 2026.
• The last three EBITDA figures came in at $109.8 million (Q2 2026), $78.9 million (Q1 2026), and $108.4 million (Q4 2025), per Business Quant data.